CRISPR stock: buy or sell?
August 22nd, 2019
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR\u002FCas9)gene-editing platform in Switzerland.
Should I buy CRISPR stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. Following a trading plan helps to make decisions easier, quicker and with less hesitations. At Stocks2.com, we use very simple but trusted and powerful trend following trading strategies. Simple things usually work the best.
Currently, CRISPR stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is CRISPR stock a buy?
Banks and financial institutions post stock ratings everyday.At Stocks2.com, we collected 10 ratings published for CRSP stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-8-1||Jefferies Financial Group||n/a||Buy|
|2019-7-31||Needham & Company LLC||n/a||Buy|
|2019-3-13||William Blair||n/a||Market Perform|
|2019-1-28||Goldman Sachs Group||Buy||Neutral|
CRISPR stock analysis
Shares of CRISPR Therapeutics stayed steady a disappointing -0.24% and closed at $48.86.
CRISPR Therapeutics stayed constant a disappointing -0.24% and closed at $48.86. Since SMA100d and SMA200d crossed up on June, CRSP price climbed $1.91 per share (4.07%). Since price and SMA200d lines crossed up on June, CRSP climbed $11.61 (31.17%).
After sliding a horrible -5.15% in a week last week, CRISPR closed this week at $48.86 and soared a beatiful 2.75%. Late July CRSP rocketed a cool 5.55% in just one week.
CRSP shows a long term strength with several rising tops and rising bottoms. It left a new bottom at $44.55 early August. Previous top ($53.90) will play as a resistance in possible new gains. Since mid June when SMA20w and SMA40w crossed up, CRSP price gained $5.98 per share (13.95%). Early June CRSP price bounced up over the SMA of 40 weeks that acted as support stopping new slides.
CRISPR stock price history
CRISPR IPO was on October 19th, 2016 at $15.00 per share1. Since then, CRSP stock surged a 225.70%, with a yearly average of 112.90%. If you had invested $1,000 in CRISPR stock in 2016, it would worth $2,257.00 today.
1: Adjusted price after possible price splits or reverse-splits.
CRISPR stock historical price chart
CRSP stock reached 52-week highs on September at $59.00, and all-time highs 2018-05-24 with a price of 73.9.
CRISPR stock price target is $51.10Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 7 price forecasts for CRSP stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-8-1||Jefferies Financial Group||Initiates||n/a||$64.00||-|
|2019-7-31||Needham & Company LLC||Reiterates||n/a||$62.00||-|
|2019-1-28||Goldman Sachs Group||Downgrades||$78.00||$40.00||-48.7%|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, CRISPR Therapeutics presented its financial report, posting a shining gain for the Earnings per Share (EPS). Analyst were expecting $-0.78 per share, but CRISPR Therapeutics posted $-0.92.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsIn 2018, CRISPR annual turnover collapsed a bloodcurdling -92.38% to $3.12 million dollars from $41.00 marked in 2017. Aligned with this, its earnings margin (compared to revenues) plunged to -5,281.08%, that is $-164.98 million.
|2015||$0.25 M||-||$-25.50 M-10325.1%||-|
|2016||$5.16 M||1,990.69%||$-23.18 M-448.8%||-9.12%|
|2017||$41 M||693.90%||$-68.36 M-166.7%||194.93%|
|2018||$3.12 M||-92.38%||$-164.98 M-5281.1%||141.35%|
Quarterly financial resultsCRISPR posted $0.12 M in sales for 2018-Q4, a -79.57% decline compared to previous quarter. Reported quarter earnings marked $-47.59 M with a profit margin of -41,382.61%. Profit margin plummed a -32,375.33% compared to previous quarter when profit margin was -9,007.28%. When comparing revenues to same quarter last year, CRISPR Therapeutics sales marked a scary correction and plunged a -99.64%. Looking back to recent quarterly results, CRISPR posted 4 positive quarters in a row.
|2017-Q2||$3.58 M||-||$-22.32 M-623.5%||-|
|2017-Q3||$2.39 M||-33.32%||$-24.71 M-1035.1%||10.69%|
|2017-Q4||$32.33 M||1,254.21%||$0.14 M0.4%||-100.57%|
|2018-Q1||$1.36 M||-95.80%||$-28.30 M-2083.9%||-20,170.92%|
|2018-Q2||$1.09 M||-19.88%||$-38.38 M-3527.6%||35.62%|
|2018-Q3||$0.56 M||-48.25%||$-50.71 M-9007.3%||32.13%|
|2018-Q4||$0.12 M||-79.57%||$-47.59 M-41382.6%||-6.15%|
|2019-Q1||$0.33 M||185.22%||$-48.41 M-14758.5%||1.72%|
CRISPR ownershipWhen you are planning to buy shares of a stock, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For CRISPR, 41.38% of all outstanding shares are owned by its staff.
In case of CRISPR Therapeutics stock, 44.50% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for CRSP stock account 0.00%, no big difference from last month.
For a better context understanding, the next table shows ownership data compared to other related companies:
|Market cap||$0.0 M||$313.7 M||$236.9 M|
|Total shares||0.0 M||120.7 M||49.3 M|
|Float shares||32.1 M||108.6 M||45.0 M|
|- Institutional holdings (%)||44.5%||95.2%||72.8%|
|- Insider holdings (%)||41.4%||2.5%||0.2%|
|Shares in short selling||0.0%||0.0%||0.0%|
|Thursday, August 22nd, 2019|
|Day range||$48.22 - $49.27|
|Average true range||$2.20|
|50d mov avg||$47.95|
|100d mov avg||$43.37|
|200d mov avg||$38.82|
CRISPR performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We picked PDL BioPharma and Pieris Pharmaceuticals as the bechmarking frame for CRISPR stock.